After Altimmune announced topline results from its 24-week trial of pemvidutide in subjects with NAFLD, Piper Sandler analyst Yasmeen Rahimi called the data "strong and encouraging" and believes this data de-risks weight loss efficacy and safety ahead of the dedicated Phase 2 MOMENTUM obesity trial. The analyst, who thinks the "pressure is off the stock" and that shares "will run into MOMENTUM interim 24-week data" due in Q1, keeps an Overweight rating and $25 price target on Altimmune shares.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly
See today’s best-performing stocks on TipRanks >>
Read More on ALT:
- Altimmune announces topline results from 24-week trial of pemvidutide
- Altimmune Announces Positive Topline Results from 24-Week (12-Week Extension) Trial of Pemvidutide in Subjects with Non-Alcoholic Fatty Liver Disease (NAFLD)
- Trial success is rocketing this NASH stock higher and sinking these peers
- Altimmune initiated with a Buy at Goldman Sachs
- Altimmune to Participate at Two Upcoming Investor Conferences